Talphera (TLPH) Q2 2024 earnings summary

Executive summary

• NEPHRO study for Niyad/nafamostat is progressing, with patient screening underway and eight academic sites finalized; FDA approved expansion to 14 sites to expedite enrollment and broaden patient access.

• Dr. Pam Palmer, co-founder and CMO, will retire in October but will continue to advise until NEPHRO study completion and potential FDA approval; Dr. Shakil Aslam appointed Chief Development Officer.

• Pre-launch commercial activities for Niyad are ongoing, focusing on market research and manufacturing readiness.

• Focused on developing and commercializing innovative therapies for medically supervised settings, with lead candidates Niyad and LTX-608 targeting anticoagulation and critical care indications.

• Divested DSUVIA to Alora in April 2023, retaining rights to certain milestone and sales-based payments, and monetized a portion of these future payments via a $8.0 million agreement with XOMA in January 2024.

Financial highlights

• Closed Q2 2024 with $14 million in cash, cash equivalents, and investments, up from $9.4 million at year-end 2023.

• Net loss for Q2 2024 was $3.8 million, improved from $4.4 million in Q2 2023; net loss per share was $0.15 (basic and diluted) for Q2 2024.

• Q2 cash operating expenses (R&D and SG&A, excluding stock-based compensation) were $4 million, up from $3.8 million year-over-year.

• Full-year cash operating expense guidance reduced to $19–$21 million from $21–$23 million.

• No revenue reported for Q2 2024; all historical DSUVIA results now classified as discontinued operations.

Outlook and guidance

• Enrollment at high-volume sites expected to accelerate in coming weeks; updated study completion and PMA filing timeline to be provided next quarter.

• Anticipated increase in operating expenses for the remainder of the year as study enrollment ramps up.

• Management expects to need additional capital to fund operations within twelve months, given current cash resources and planned expenditures.

• Breakthrough Device Designation from FDA may expedite potential approval of nafamostat in 2025.

• Focus remains on completing the Niyad registrational trial and evaluating timing for pre-filled syringe product NDA submissions.